Pharmaceutical News

RSS

Cincinnati Children's research leads to approval of new drug for hypereosinophilic syndrome

Following two decades of research on a group of rare diseases called hypereosinophilic syndrome at Cincinnati Children's Hospital Medical Center, the U.S. Food and Drug Administration has approved the drug Nucala (mepolizumab) for use in the treatment of patients with hypereosinophilic syndrome.

28 Sep 2020

Researchers study placebo effect in nausea treatment at the molecular level

The molecular bases of the placebo effect are poorly understood. A team led by Ludwig-Maximilians-Universitaet in Munich researcher Karin Meissner has now studied the phenomenon in the context of nausea, and identified specific proteins that correlate with its favorable impact.

28 Sep 2020

Newer Type 2 diabetes medications could reduce kidney, heart disease risks

Two newer groups of medications prescribed primarily for Type 2 diabetes treatment (SGLT2 inhibitors and GLP-1 receptor agonists) could significantly reduce risks associated with chronic kidney disease (CKD) and heart disease.

28 Sep 2020

NIH awards $1.9 million STTR grant to fast track new class of non-opioid pain relievers

The National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NIH) has awarded a $1.9 million Fast-Track Small Business Technology Transfer grant to South Rampart Pharma.

25 Sep 2020

University of Minnesota receives funding to initiate research on diabetes drug as a COVID-19 treatment

University of Minnesota Medical School researchers received funding from the Parsemus Foundation to initiate research on the widely-used diabetes medication, metformin, available globally as an inexpensive generic drug for prevention and treatment for COVID-19.

25 Sep 2020

FDA approves first drug for patients with hypereosinophilic syndrome in nearly 14 years

Today, the U.S. Food and Drug Administration approved Nucala (mepolizumab) for adults and children aged 12 years and older with hypereosinophilic syndrome (HES) for six months or longer without another identifiable non-blood related cause of the disease.

25 Sep 2020

Researchers advance novel compounds to help treat C. difficile infection

Clostridioides difficile, or C. diff, is the leading cause of health care-associated infection in the U.S.

25 Sep 2020

BIOCAD to produce liquid vaccine for COVID-19 treatment

Clinical trials of the vaccine are currently underway. The &laquoSputnik V» is the two-component vaccine. Revaccination is carried out at intervals of 3-4 weeks. Moreover, with the repeated introduction of a particle of coronavirus RNA, it is covered with a new adenovirus.

25 Sep 2020

Study assesses cardiovascular and renal outcomes for ertugliflozin in patients with type 2 diabetes

A new study led by a cardiologist from Brigham and Women's Hospital has assessed the cardiovascular and renal outcomes for ertugliflozin, an SGLT2 inhibitor prescribed for patients with type 2 diabetes to help them control blood sugar levels

25 Sep 2020

Researchers compare the effect of two anti-hypertensive drugs on post-exercise hypotension

Researchers in the University of São Paulo's School of Physical Education and Sports (EEFE-USP) in Brazil compared the effect of two widely used classes of anti-hypertensive drugs on post-exercise hypotension, an expected and beneficial fall in blood pressure after a session of aerobic exercise, especially in the late afternoon or early evening.

25 Sep 2020

Berlin researchers are pursuing the development of passive vaccination

Researchers at the German Center for Neurodegenerative Diseases (DZNE) and Charité - Universitätsmedizin Berlin have identified highly effective antibodies against the coronavirus SARS-CoV-2 and are now pursuing the development of a passive vaccination.

25 Sep 2020

An overview of withdrawal syndromes following discontinuation of psychotropic drugs

The current issue of Psychotherapy and Psychosomatics reports an article that analyzes the data that are available on what may happen when psychotropic drugs are discontinued.

24 Sep 2020

FDA takes actions to help provide safe, more affordable drugs to Americans

Today, the U.S. Department of Health and Human Services and the U.S. Food and Drug Administration took actions to help provide safe, effective, and more affordable drugs to American patients as part of the Safe Importation Action Plan, fulfilling the aspect of the July Executive Order on drug pricing to complete the rulemaking to allow states to import certain prescription drugs from Canada.

24 Sep 2020

Researchers investigate molecular mechanism responsible for hypnotic effects of thalidomide

Thalidomide is a medication with several different effects, one of which is promoting sleep in the context of insomnia.

24 Sep 2020

Gruthan Bioscience to develop new class of cholesterol-lowering drugs

Gruthan Bioscience, LLC, a Medical University of South Carolina startup based in Charleston, South Carolina, received a Small Business technology Transfer (STTR) award from the National Heart, Blood and Lung Institute in August to take the next step in developing a novel class of cholesterol-lowering drugs to treat familial hypercholesterolemia.

24 Sep 2020

FDA announces requirement of class-wide labeling changes for benzodiazepines

The U.S. Food and Drug Administration announced today in a Drug Safety Communication that it is requiring an update to the Boxed Warning, the agency's most prominent safety warning, and requiring class-wide labeling changes for benzodiazepines to include the risks of abuse, misuse, addiction, physical dependence and withdrawal reactions to help improve their safe use.

23 Sep 2020

Drugs used to treat HIV and hepatitis B could be repurposed to prevent type 2 diabetes

A group of drugs used to treat HIV and hepatitis B could be repurposed to prevent type 2 diabetes, a new study suggests.

23 Sep 2020

Cardiovascular adverse events linked to hydroxychloroquine and chloroquine

As the antimalarial drugs hydroxychloroquine and chloroquine have drawn attention as potential therapies for COVID-19 and are being widely used off-label, it's now more important than ever to have a thorough assessment of the safety of these medications.

23 Sep 2020

HIV drugs cause immune-system changes that can improve resistance to viral infections

Drugs currently used to keep the HIV virus in check also cause immune-system changes that might make humans better able to resist viral infections – but might also cause harmful inflammation, according to a study published today in Cell Reports Medicine.

23 Sep 2020

New book sheds light on addiction to psychoactive drugs

Cold Spring Harbor Laboratory Press (CSHLP) announced the publication of Addiction, 2e, now available on its website in ebook and hardcover formats.

23 Sep 2020

Pharmaceutical News

Cincinnati Children's research leads to approval of new drug for hypereosinophilic syndrome

Researchers study placebo effect in nausea treatment at the molecular level

Newer Type 2 diabetes medications could reduce kidney, heart disease risks

NIH awards $1.9 million STTR grant to fast track new class of non-opioid pain relievers

University of Minnesota receives funding to initiate research on diabetes drug as a COVID-19 treatment

FDA approves first drug for patients with hypereosinophilic syndrome in nearly 14 years

Researchers advance novel compounds to help treat C. difficile infection

BIOCAD to produce liquid vaccine for COVID-19 treatment

Study assesses cardiovascular and renal outcomes for ertugliflozin in patients with type 2 diabetes

Researchers compare the effect of two anti-hypertensive drugs on post-exercise hypotension

Berlin researchers are pursuing the development of passive vaccination

An overview of withdrawal syndromes following discontinuation of psychotropic drugs

FDA takes actions to help provide safe, more affordable drugs to Americans

Researchers investigate molecular mechanism responsible for hypnotic effects of thalidomide

Gruthan Bioscience to develop new class of cholesterol-lowering drugs

FDA announces requirement of class-wide labeling changes for benzodiazepines

Drugs used to treat HIV and hepatitis B could be repurposed to prevent type 2 diabetes

Cardiovascular adverse events linked to hydroxychloroquine and chloroquine

HIV drugs cause immune-system changes that can improve resistance to viral infections

New book sheds light on addiction to psychoactive drugs

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Latest News